Spruce Biosciences to Participate in September Investor Conferences

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB), a biopharmaceutical company, announced participation in four investor conferences this September. The conferences include H.C. Wainwright Global Investment Conference (Sept 13-14), Baird 2021 Global Healthcare Conference (Sept 14-15), Oppenheimer Fall Healthcare Life Sciences Summit (Sept 20-22), and SVB Leerink CybeRx Series (Sept 22-23). The company is focused on developing therapies for rare endocrine disorders, particularly tildacerfont for classic congenital adrenal hyperplasia and polycystic ovary syndrome.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in four upcoming investor conferences taking place virtually throughout the month of September:

• H.C. Wainwright 23rd Annual Global Investment Conference
  Date: September 13 – 14, 2021
  Format: Company presentation (available September 13 at 7:00 am ET) and 1x1 meetings

• Baird 2021 Global Healthcare Conference
  Date: September 14 – 15, 2021
  Format: Company presentation (September 15 at 1:25 pm ET) and 1x1 meetings

• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
  Date: September 20 – 22, 2021
  Format: Company presentation (September 21 at 11:35 am ET) and 1x1 meetings

• SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event
  Date: September 22 – 23, 2021
  Format: 1x1 meetings

Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005724/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburytrout.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

What investor conferences will Spruce Biosciences attend in September 2021?

Spruce Biosciences will attend the H.C. Wainwright Global Investment Conference, Baird 2021 Global Healthcare Conference, Oppenheimer Fall Healthcare Life Sciences Summit, and SVB Leerink CybeRx Series.

When is Spruce Biosciences presenting at the H.C. Wainwright Global Investment Conference?

Spruce Biosciences will present at the H.C. Wainwright Global Investment Conference on September 13-14, 2021.

What is the focus of Spruce Biosciences' research and development?

Spruce Biosciences focuses on developing novel therapies for rare endocrine disorders, including classic congenital adrenal hyperplasia and polycystic ovary syndrome.

What is the ticker symbol for Spruce Biosciences?

The ticker symbol for Spruce Biosciences is SPRB.

When will Spruce Biosciences present at the Oppenheimer Fall Healthcare Life Sciences Summit?

Spruce Biosciences will present at the Oppenheimer Fall Healthcare Life Sciences Summit on September 21, 2021.